source
- Updated: Allen Institute launches $400M effort to turn brain atlas lessons into medicinesA Seattle-based nonprofit known for basic brain research is launching a $400 million initiative to translate its knowledge into drug development for neurodegenerative diseases, including Alzheimer'…Endpoints · 1mo ago↗ source
- RallyBio tries again for reverse merger, this time with AvenzoIt's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.BioPharma Dive · 2mo ago↗ source
- The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that wayHow much is a regulatory shortcut worth? The cost of a priority review voucher, which shortens the FDA’s standard review time by about four months, has roughly doubled in the last few years. The FD…